TheraSphere™ Y-90 Glass Microspheres

Transplant candidacy

Help get HCC patients to transplant

TheraSphere^TM Y-90 Glass Microspheres is the market leader and first FDA approved transarterial radiation therapy for hepatocellular carcinoma (HCC), delivering targeted damage to the tumor, sparing healthy tissue, and preserving treatment options.

TheraSphere is an efficient and powerful therapy for HCC that safely delivers high-dose radiation which can:

Aid in achieving surgical candidacy
Preserve liver transplant eligibility
Support strong Overall Survival (OS) outcomes

Download the TheraSphere Transplant Brochure

Most utilized LRT bridging strategy for liver transplant candidates with HCC in the US¹

Analysis of data from the Organ Procurement and Transplant Network (OPTN) reflects the increasing adoption by many transplant centers of transarterial radioembolization (TARE) as the primary LRT option surpassing both chemoembolization and thermal ablation.¹

Bridging and Downstaging

TheraSphere provides a strong local tumor response and has been studied in patients intended to downstage tumors for transplant or bridge within Milan criteria.

82%

of patients bridged to transplant.²

58%

of T3 patients downstaged to T2³

74%

of HCC patients showed complete or extensive tumor necrosis.²

See bridging and downstaging data

See all clinical data

Transforming HCC Care: Innovations in Treatment and Transplant Pathways

Watch how a healthcare institution has adapted its liver cancer treatment and transplant pathways in response to changes in the transplant allocation system. The emphasis is on the Multidisciplinary Liver Conference and the integration of innovative technologies, specifically TheraSphere Y-90 Microsphere therapy, which has led to durable outcomes comparable to leading centers in radioembolization. Discover key clinical studies, specific case examples, and insights into their own outcomes demonstrating this impact.

Surgical options after treatment

Transplant surgeon Dr. Talia Baker uses TheraSphere with her HCC patients, like Nicole, to aid in achieving surgical candidacy.

Y-90 vs. other LRTs

Explore clinical data for Y-90 vs. other locoregional therapy (LRT) options

PREMIERE and TRACE trials

Comparison of TARE treatment using TheraSphere to DEB-TACE** and cTACE in patients with HCC shows longer time to tumor progression as a cost-effective, efficient treatment option.

View the PREMIERE and TRACE trials

Treatment center finder

Instantly locate treatment centers administering TheraSphere near you for your HCC patients.

Find a treatment center near you

References

Salem R, Kwong AJ, Kim N, Sze DY, Mehta N, YTTRIUM-90 RADIOEMBOLIZATION HAS BECOME THE MOST UTILIZED BRIDGING TREATMENT FOR LIVER TRANSPLANT CANDIDATES IN THE UNITED STATES, Journal of Vascular and Interventional Radiology (2024), doi: https://doi.org/10.1016/j.jvir.2024.10.034.
Gabr, A., Kulik, L., Mouli, S., Riaz, A., Ali, R., Desai, K., Mora, R.A., Ganger, D., Maddur, H., Flamm, S., Boike, J., Moore, C., Thornburg, B., Alasadi, A., Baker, T., Borja-Cacho, D., Katariya, N., Ladner, D.P., Caicedo, J.C., Lewandowski, R.J. and Salem, R. (2020), Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort. Hepatology. Accepted Author Manuscript. doi:10.1002/hep.31318
Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-8.

TheraSphere indications, safety, and warnings

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.

My account